AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01242683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivamos Activos Fair Oaks Program
Description: Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms.
Study NCT01242683 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Vivamos Activos Fair Oaks Program
Description: Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms.
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy without Carboplatin
Description: Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks
Study NCT02066220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced-intensity maintenance chemotherapy
Description: Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Carboplatin
Description: Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
Study NCT02066220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Description: Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients).
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WNT-HR < 16 years
Description: Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WNT-HR >= 16 years
Description: Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
Study NCT02066220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SHH-TP53 M0
Description: * with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SHH-TP53 M+ (germline)
Description: craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
Study NCT02066220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SHH-TP53 (somatic)
Description: craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
Study NCT02066220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastin Maintenance
Description: Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
Study NCT03327454 — intervention group
Intervention type: BIOLOGICAL
Intervention: Benepali
Description: Administered as specified in the treatment arm.
Study NCT00767949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iSONEP
Description: single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
Study NCT03404427 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normal sleep night
Description: Usual hours of sleep
Study NCT03404427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleepless night
Description: Total sleep deprivation the first night
Study NCT01460368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT01460368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01460368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally
Study NCT04650776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat strain
Description: The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
Study NCT01517685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic flax seed oil
Description: 2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
Study NCT01517685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Pleiotropic Pathway Modifier
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab
Study NCT02269046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion
Description: Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
Study NCT02269046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 10mg/d,p.o,12 weeks.
Study NCT02269046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity
Study NCT02269046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity
Study NCT02269046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Lifestyle Change
Description: * Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT04386031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Throat culture for fungal pathogens
Description: Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
Study NCT01820156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Respiratory Polygraphy
Study NCT01820156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Polysomnography
Study NCT01977937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 250mg/5mL NDC:59762-5025-01
Study NCT01977937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simple Syrup
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, nedaplatin, and capecitabine
Description: Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin
Description: Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, and fluorouracil
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study NCT03310619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: CC-99282
Study NCT00137202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Zofran)
Study NCT00137202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine (Benadryl)
Study NCT01257191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Black
Description: source: commercial
Study NCT01257191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust Particles
Description: source: diesel engine
Study NCT01257191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fine Concentrated Ambient Particles
Description: source: concentrated ambient air
Study NCT01257191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafine Concentrated Ambient Particles
Description: source: concentrated ambient air
Study NCT01257191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline solution
Study NCT03424980 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Tyrosine kinase inhibitors
Description: Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
Study NCT00957216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: placebo: 2 wafers 4 times a day
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
Study NCT04423393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection or intravenous infusion.
Study NCT04423393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
Study NCT02867839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus S-1
Description: 8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
Study NCT02867839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 only
Description: 16 cycles of adjuvant chemotherapy with S-1 only
Study NCT00957216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 300mg wafers; 2 wafers 4 times a day
Study NCT04489017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT
Description: PEA-LUT administration at the oral dosage of 700 mg x 2/day
Study NCT04489017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO administration at the oral dosage of 700 mg x 2/day
Study NCT04202458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial tenecteplase administration
Description: Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
Study NCT03078478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily
Study NCT03078478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: For subcutaneous (s.c., under the skin) injection once daily
Study NCT03302065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT03302065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study NCT04187924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
Study NCT04187924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX + Autogenic drainage
Description: SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
Study NCT01857206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammalian cell based flu vaccine
Study NCT01857206 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg based flu vaccine
Study NCT01117844 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
Study NCT00949039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolated pelvis perfusion
Description: injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
Study NCT00949039 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: chemotherapy and/or radiotherapy and/or surgery
Study NCT00949039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study NCT01653314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megavec
Study NCT01653314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megavec
Study NCT01653314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec
Study NCT01653314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glivec
Study NCT03344705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
Study NCT03344705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Two days before cell infusion,all patients will be treated with fludarabine for 3 days
Study NCT03344705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
Study NCT02834741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NYX-2925
Description: NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study NCT03510715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, and capecitabine
Description: Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
Study NCT03503136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, nedaplatin, and fluorouracil
Description: Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study NCT00828854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat 5 mg PO every week
Study NCT00828854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor (AI) Therapy
Description: AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.